IDEXX Laboratories (NASDAQ:IDXX) Issues FY 2026 Earnings Guidance

IDEXX Laboratories (NASDAQ:IDXX) updated its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 14.960-15.160 for the period, compared to the consensus EPS estimate of 14.860. The company issued revenue guidance of $4.7 billion-$4.8 billion, compared to the consensus revenue estimate of $4.7 billion.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on IDXX shares. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Citigroup lifted their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. JPMorgan Chase & Co. decreased their price objective on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a report on Friday, October 16th. The Goldman Sachs Group started coverage on IDEXX Laboratories in a research note on Friday, October 16th. They issued a “buy” rating and a $740.00 price objective for the company. Finally, Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Seven investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $719.55.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $672.04 on Wednesday. IDEXX Laboratories has a 1 year low of $500.61 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.19 and a quick ratio of 0.87. The firm has a market cap of $52.94 billion, a price-to-earnings ratio of 45.32 and a beta of 1.55. The company has a fifty day moving average price of $538.81 and a 200-day moving average price of $573.69.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, beating analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.19 billion. During the same period last year, the firm earned $3.22 earnings per share. The firm’s revenue was up 9.9% on a year-over-year basis. As a group, equities research analysts predict that IDEXX Laboratories will post 15.05 EPS for the current fiscal year.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the business’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.79% of the company’s stock.

Key Stories Impacting IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: IDEXX reported Q3 revenue of about $1.21 billion and EPS of $3.96, both ahead of analyst expectations. Recurring veterinary diagnostics sales were a growth driver, and the company raised its FY2026 EPS outlook to $14.96–$15.16; revenue guidance is $4.7–$4.8 billion. Reuters article
• Positive Sentiment: Morgan Stanley reiterated an Overweight/Buy view and raised its price target to $810 from $805, citing strong execution and the improved outlook. UBS also characterized the results as strong despite a lackluster veterinary-visit environment. Analyst rating article
• Positive Sentiment: Recent technical coverage noted that IDXX moved above its 200-day moving average, a signal some investors interpret as supportive of a longer-term trend. Zacks technical analysis
• Negative Sentiment: Veterinary visits remain lackluster, and coverage flagged a softer margin outlook. These factors could limit growth or profitability even as diagnostics sales and the full-year earnings forecast improve. Motley Fool article

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.